Patterson Companies (PDCO)
(Delayed Data from NSDQ)
$20.27 USD
-0.01 (-0.05%)
Updated Oct 8, 2024 03:59 PM ET
After-Market: $20.27 0.00 (0.00%) 7:30 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.27 USD
-0.01 (-0.05%)
Updated Oct 8, 2024 03:59 PM ET
After-Market: $20.27 0.00 (0.00%) 7:30 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
Zacks News
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
SentinelOne (S) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
SentinelOne's (S) second-quarter fiscal 2024 results are likely to reflect the benefits of an expanding clientele amid challenging macroeconomic conditions.
Should You Buy Patterson Companies (PDCO) Ahead of Earnings?
by Zacks Equity Research
Patterson Companies (PDCO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio
by Zacks Equity Research
OPKO Health's (OPK) potential in RAYALDEE raises optimism about the stock.
Is a Beat Likely for Cooper Companies (COO) in Q3 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.
Medtronic's (MDT) Inceptiv Spinal Cord Stimulator Gets CE Mark
by Zacks Equity Research
Medtronic's (MDT) Inceptiv SCS System is the first Medtronic SCS device to offer a closed-loop feature that senses each person's unique biological signals.
BrainsWay (BWAY) Expands Foothold in Taiwan With Deep TMS
by Zacks Equity Research
The collaboration between BrainsWay (BWAY) and Unison Healthcare Group signifies a coordinated effort to enhance access and awareness of Deep TMS in Taiwan.
LabCorp (LH) Suffers From Lower COVID Test Sales, Macro Woes
by Zacks Equity Research
Labcorp's (LH) Early Development Research Laboratories business continues to be constrained by NHP-related supply-chain issues.
VMware (VMW) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
VMware's (VMW) second-quarter fiscal 2024 performance is likely to have reflected the benefits of a strong portfolio and expanding partner base.
Broadcom (AVGO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Broadcom's (AVGO) fiscal third-quarter results are likely to reflect strong networking solutions revenues, driven by robust adoption of Tomahawk 4 and Jericho switches.
CrowdStrike (CRWD) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
CrowdStrike's (CRWD) second-quarter results are likely to reflect the benefits of the strong demand for its security solutions, contributions from collaborations and newly added customers.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Salesforce (CRM) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
While digital transformation and the growing adoption of generative AI-enabled solutions are likely to have boosted Salesforce's (CRM) top line in Q2, cost-cutting initiatives are expected to have driven the bottom line.
OKTA Gears Up to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
OKTA's second-quarter fiscal 2024 results are expected to reflect the continued adoption of Workforce and Customer Identity solutions.
Charles River (CRL) Collaborates With Fondazione Telethon
by Zacks Equity Research
Charles River (CRL) is excited about Fondazione Telethon's collaboration to produce HQ plasmid DNA for the lentivirus used in ex vivo gene therapy developed by Fondazione Telethon.
HP Inc. (HPQ) Set to Release Q3 Earnings: What's in Store?
by Zacks Equity Research
HP Inc.'s (HPQ) third-quarter performance is likely to have been negatively impacted by the weak demand for PCs, high inventory levels and unfavorable currency exchange rates.
Is a Beat Likely for Patterson Companies (PDCO) in Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement at both Dental and Animal Health segments.
NextGen (NXGN) to Offer AI-Based Patient Engagement Solutions
by Zacks Equity Research
NextGen (NXGN), in alliance with Luma Health, is set to offer AI-enhanced solutions for patient communications to ambulatory organizations nationwide.
Catalent (CTLT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q4 results are likely to be affected by soft segmental performances.
Masimo's (MASI) Stork Baby Monitor Now Available Across U.S.
by Zacks Equity Research
The latest U.S. availability of Masimo's (MASI) Stork smart home baby monitoring system is likely to provide a continuous and accurate view of babies' health data.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX) on the expanded global installed base of more than 3,250 Panthers instruments, representing the catalyst for sustained growth.
Veeva Systems (VEEV) to Support Civica Rx Quality Control
by Zacks Equity Research
Veeva Systems' (VEEV) Vault LIMS will streamline internal testing and manufacturing while promoting lead time adherence.
Hewlett Packard (HPE) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
The growing demand for cloud services amid the ongoing digital transformation trend is likely to aid Hewlett Packard's (HPE) third-quarter fiscal 2023 results.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Fresenius Medical's (FMS) New HHD Device to Increase Portability
by Zacks Equity Research
Fresenius Medical (FMS) gets FDA clearance for Versi HD with GuideMe Software, a portable, home hemodialysis device with an easy-to-use graphical interface providing easier training experiences.